Valneva dips then recovers: what's really happening with the stock and the VLA2001 vaccine?
If you've been following this French biotech for the past decade, you know that rollercoaster rides are part of the daily grind. But what happened to Valneva this week would make even the most hardened investors wince. The stock suddenly broke below €4.35, flirting with €3.89 before showing some signs of a rebound. A jolt like this always throws retail investors into a bit of a panic. So, what's behind this latest turnaround?
Solid financial results, but a fickle market mood
Let's put things in perspective. According to the financial results released a few days ago, the company's finances are in good shape. Revenue is there, cash flow is steady, and the development of vaccine candidates is progressing. So why the drop? Because in the stock market, especially for a company of this size, the devil is in the expectations. The market was probably hoping for a more aggressive outlook, or more groundbreaking news on the progress of its well-known Lyme disease vaccine.
But this is about science, not magic. Thomas Lingelbach, the CEO, says it every time he speaks: developing preventative vaccines for infectious diseases doesn't happen overnight. VLA15 (the name of their Lyme disease candidate) is arguably the most closely watched project in the industry, because if it succeeds, it would be the first modern-day "cash cow" against this disease. But until that final green light is given, the share price remains under pressure.
VLA2001, the COVID vaccine that changed the game... and expectations
We shouldn't forget where the company came from. With VLA2001, Valneva proved it could compete with the big players. This inactivated virus vaccine, used particularly in strict protocols, was a much-needed lifeline. For those following regulatory aspects, the Generic Protocol for ECDC Studies of COVID-19 Vaccine Effectiveness Against Confirmed SARS-CoV-2 Using Healthcare Worker Cohorts: Version 3.0 remains an important benchmark for assessing its real-world effectiveness.
But today, the market has a very short memory. The COVID era is behind us, and investors don't want to hear about legacy vaccines anymore. They want something new, something disruptive. And right now, Valneva finds itself in a bit of a lull, caught between the end of the COVID euphoria and the still-ongoing maturation of its Lyme pipeline. This is often the period where share prices suffer the most, because traders don't like the void. They prefer blockbuster quarterly announcements over periods of quiet waiting.
Reasons for optimism (or not) going forward
So, what should you do if you have Valneva in your portfolio or are eyeing the stock with interest? Here are a few points worth considering:
- Cash and visibility: The company has secured funding and partnerships. It's not going to disappear tomorrow. The financial results confirm this: there's enough to keep the wheels turning until the next major milestones.
- The Lyme timeline: VLA15 is the main catalyst. The next data readouts, if positive, could literally send the stock soaring. It's a binary situation, but with enormous potential.
- Thomas Lingelbach's track record: He's no beginner. He's weathered far worse storms than this minor market chill. His strategy, focused on developing preventative vaccines, remains consistent.
On the stock market, emotions are often amplified with this type of stock. The drop below €4.35 triggered stop-losses, automatic sales, and that mechanically amplified the move. It's classic. What's more interesting is seeing whether the stock manages to stabilise above that psychological threshold in the coming sessions. If it does, the technical rebound could be just as sharp as the fall.
Let's be honest, betting on Valneva today is betting on the biotech of tomorrow, with all the risks and rewards that entails. But those who held on during the uncertain phases for VLA2001 will remember: when the science delivers, the market eventually follows.